Zacks Investment Research upgraded shares of CYTOKINETCS INC (CYTK) from NEUTRAL to OUTPERFORM on February 11, 2013, with a target price of $1.20.
CYTOKINETCS is a different kind of company. It is increasingly unusual that an emerging growth biotechnology company would be dedicated to the discovery, development and commercialization of therapeutics. Similarly, it is more and more uncommon for a biopharmaceutical company to tackle the pursuit of new treatments for multiple disease areas, including cancer and cardiovascular diseases. However, the most important distinguishing feature of Cytokinetics is instead found in our commitment to innovation that has translated our focus on the cytoskeleton into a Research and Development pipeline of multiple, first-in-class compounds. All of the programs we are pursuing offer entirely novel therapeutic approaches to severe unmet clinical needs. The reason is simple. Innovative therapeutics are much more likely to bring substantial benefits to patients.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CYTOKINETCS INC (CYTK),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment